Aclaris Therapeutics (NASDAQ:ACRS – Free Report) had its price target reduced by Scotiabank from $15.00 to $9.00 in a report released on Friday morning,Benzinga reports. They currently have a sector outperform rating on the biotechnology company’s stock. Seve…
Aclaris Therapeutics (NASDAQ:ACRS) Price Target Lowered to $9.00 at Scotiabank
